Halaven® (eribulin) continues to be available for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens, even though recent guidance from the National Institute of Health and Care Excellence (NICE) is not recommending eribulin for use in an earlier setting.
In 2016 eribulin became the first breast cancer treatment to be recommended by NICE in nearly a decade for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens which may include an anthracycline or a taxane, and capecitabine.
More recently, NICE has been assessing eribulin for the treatment of patients with locally advanced or metastatic breast cancer after one chemotherapy regimen.
Approximately 55,200 women are diagnosed with breast cancer in England each year, of whom one third subsequently develop metastatic disease. Only 15% of women with metastatic breast cancer will survive beyond five years.
Gary Hendler, Chief Commercial Officer Eisai Oncology Business Group, Chairman and CEO Eisai EMEA, said: “Eisai is yet again extremely disappointed with a decision from NICE. Denying earlier access to it for these patients will affect their outcomes and as a company focused on making a positive difference to the lives of patients and their families, NICE’s decision concerns us greatly. Thankfully patients can still access eribulin in the third line.”
Dr. Hartmut Kristeleit, Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust, said: “I’ve been using Halaven® (eribulin) in the treatment of breast cancer for over six years. Although the second line use of this drug was not approved by NICE, I am delighted that the third line approval for advanced metastatic breast cancer remains.”
Eribulin was first approved and launched in the UK in 2011 and is currently approved in 64 countries around the world including all of the European Union, Canada, United States, Russia, Switzerland, South Korea, Japan and Singapore.